BELLOMO, GIOVANNI
 Distribuzione geografica
Continente #
AS - Asia 727
NA - Nord America 720
EU - Europa 403
SA - Sud America 130
AF - Africa 19
OC - Oceania 6
Totale 2.005
Nazione #
US - Stati Uniti d'America 698
SG - Singapore 314
HK - Hong Kong 128
BR - Brasile 111
IT - Italia 111
CN - Cina 110
DE - Germania 57
IE - Irlanda 57
RU - Federazione Russa 49
KR - Corea 48
VN - Vietnam 48
FI - Finlandia 27
GB - Regno Unito 23
IN - India 17
JP - Giappone 17
CA - Canada 14
NL - Olanda 14
RO - Romania 11
PL - Polonia 10
BD - Bangladesh 8
FR - Francia 8
AT - Austria 7
ES - Italia 7
IQ - Iraq 7
ZA - Sudafrica 7
AR - Argentina 6
NZ - Nuova Zelanda 5
SE - Svezia 5
TR - Turchia 4
UZ - Uzbekistan 4
VE - Venezuela 4
CO - Colombia 3
ID - Indonesia 3
LT - Lituania 3
PK - Pakistan 3
PY - Paraguay 3
SA - Arabia Saudita 3
TN - Tunisia 3
IS - Islanda 2
JM - Giamaica 2
KE - Kenya 2
MD - Moldavia 2
MX - Messico 2
NP - Nepal 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
BG - Bulgaria 1
BY - Bielorussia 1
CL - Cile 1
CM - Camerun 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
DZ - Algeria 1
EC - Ecuador 1
GE - Georgia 1
GM - Gambi 1
GY - Guiana 1
HR - Croazia 1
HT - Haiti 1
IR - Iran 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
PA - Panama 1
PG - Papua Nuova Guinea 1
PT - Portogallo 1
RE - Reunion 1
SD - Sudan 1
TJ - Tagikistan 1
TW - Taiwan 1
ZM - Zambia 1
Totale 2.005
Città #
Singapore 213
Hong Kong 127
Chandler 83
Ashburn 70
Dublin 57
Boardman 56
Seoul 48
Los Angeles 40
Perugia 36
Santa Clara 32
Beijing 24
Munich 23
Piscataway 23
Moscow 21
New York 20
San Mateo 18
Ho Chi Minh City 17
Tokyo 16
The Dalles 13
Altamura 12
Dallas 12
Helsinki 11
São Paulo 11
Turku 11
Brooklyn 10
Timisoara 10
Lawrence 9
Medford 9
Nuremberg 9
Princeton 9
Rome 9
Wilmington 9
Chennai 8
Hanoi 8
Milan 8
Warsaw 8
Denver 7
Hefei 7
Boston 6
Houston 6
London 6
Montreal 6
Phoenix 6
Redmond 6
Andover 5
Auckland 5
Columbus 5
Dong Ket 5
Falkenstein 5
Falls Church 5
Lappeenranta 5
Manchester 5
Poplar 5
Stockholm 5
Vienna 5
Amsterdam 4
Atlanta 4
Da Nang 4
Johannesburg 4
Orem 4
Secaucus 4
Baghdad 3
Chicago 3
Curitiba 3
Des Moines 3
Groningen 3
Mumbai 3
Newark 3
Newquay 3
Rio de Janeiro 3
Tashkent 3
Toronto 3
Turin 3
Ankara 2
Belém 2
Betim 2
Brasília 2
Brixen 2
Charlotte 2
Córdoba 2
Florence 2
Frankfurt am Main 2
Genoa 2
Goiânia 2
Haiphong 2
João Pessoa 2
Miami 2
Minneapolis 2
Nairobi 2
Pittsburgh 2
Porto Alegre 2
Providence 2
Redwood City 2
Reykjavik 2
Santo André 2
Sargodha 2
Seattle 2
Shanghai 2
Thái Bình 2
Tianjin 2
Totale 1.319
Nome #
Identification of natural products able to counteract the formation of advanced glycation end-products (AGEs) sustaining muscle atrophy 121
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment 104
A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies 91
Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for α-synuclein measurement 86
CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment 75
Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer's Disease 71
Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: Do fresh vs frozen samples differ? 71
Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview 63
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease 63
An unbalanced synaptic transmission: Cause or consequence of the amyloid oligomers neurotoxicity? 62
Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease 61
Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics 59
Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid 58
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward 58
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 57
Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays 56
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: Disease staging by NF-L, p-tau181, and GFAP 55
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay 54
Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD 53
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 52
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease 51
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 50
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease 50
Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer’s disease biomarkers 49
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers 49
LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes 47
CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions 44
Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias 43
The Immune Signature of CSF in Multiple Sclerosis with and without Oligoclonal Bands: A Machine Learning Approach to Proximity Extension Assay Analysis 43
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts 43
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease 42
CSF neurosecretory proteins VGF and neuroserpin in patients with Alzheimer's and Lewy body diseases 42
Lipoproteins and α-synuclein in cerebrospinal fluid in Parkinson's disease: "Dangerous liaisons" on the road to neurodegeneration? 37
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment 33
Research advancement in fluid biomarkers for Parkinson's disease 30
Studying Alzheimer's disease through an integrative serum metabolomic and lipoproteomic approach 23
Totale 2.046
Categoria #
all - tutte 10.463
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.463


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 0 0 0 3 0 0 0 0 3 7
2021/202264 1 10 2 0 2 5 4 13 4 7 7 9
2022/2023259 9 60 8 17 19 22 0 20 91 1 8 4
2023/2024223 10 16 12 6 7 1 34 6 49 11 27 44
2024/2025680 7 55 51 37 54 44 55 66 115 43 101 52
2025/2026787 95 119 62 197 208 106 0 0 0 0 0 0
Totale 2.046